Publication

Article

Internal Medicine World Report

August 2014
Volume

Is Time to First Morning Cigarette a Good Marker of Lung Cancer Risk?

Author(s):

Using the metric of time to first cigarette after waking was found to help improve efficiency and reduce false-positive detection in lung cancer screening, a new case-control study suggests.

Using the metric of time to first cigarette after waking (TTFC) was found to help improve efficiency and reduce false-positive detection in lung cancer screening, a new case-control study suggests.

Fangyi Gu, ScD, MD, of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, and colleagues examined the association between TTFC and lung cancer using logistic regression and estimated lung cancer incidence of levels of TTFC and intensity, duration, and pack-years using absolutely risk regression. The researchers followed 3249 ever-smokers (1812 case subject; 1437 controls) from a population-based study in Italy. The study was published in the July 2014 issue of the Journal of the National Cancer Institute.

Compared with smokers with TTFC greater than 60 minutes, the lung cancer odds ratios (OR) for TTFC of 31 to 60 minutes, 6 to 30 minutes, and 5 or fewer minutes (by increasing dependency) were 2.57% (95% confidence interval [CI] = 2.03-3.26), 2.27 (95% CI, 1.79-2.88), and 3.50 (95% CI, 2.64-4.64), respectively (Ptrend <.0001).

The average lung cancer incidence rates for smokers of 1 to 10, 11 to 20, 21 to 30, and more than 30 cigarettes per day were consistently higher among smokers with TTFC of 60 or fewer minutes versus more than 60 minutes.

The researchers concluded that lung cancer risk increases with shorter TTFC; thus the nicotine-dependency measure of TTFC increases lung cancer risk stratification beyond standard measures of smoking. Assessing TTFC may improve lung cancer risk prediction and can potentially be useful in lung cancer screening and smoking cessation programs.

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
Discussing Use of Vaping Among Students, Conversations About Vaccines
© 2024 MJH Life Sciences

All rights reserved.